Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 December;55(6) > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 December;55(6):648-54

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

REVIEWS  IMAGING OF THERAPY RESPONSE IN ONCOLOGY


The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 December;55(6):648-54

Copyright © 2012 EDIZIONI MINERVA MEDICA

language: English

Therapy response assessment in radiotherapy of lung cancer

Van Elmpt W. 1, Pöttgen C. 2, De Ruysscher D. 1

1 Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; 2 Department of Radiation Oncology, University Hospital Essen, Essen, Germany


PDF  


Radiotherapy represents an important therapeutic modality in the treatment of lung cancer. Treatment response assessment after high-dose radiotherapy with or without concurrent chemotherapy using conventional imaging methods is limited since normal tissue appearance might resemble tumour recurrence very close. Positron emission tomography (PET) based imaging has been introduced in this situation with great enthusiasm and provides useful additional information on the biologic characteristics of the irradiated region, be it tumour or healthy lung tissue, provided some marginal conditions are taken into account. Furthermore, biologic imaging seems highly appealing for treatment guidance especially during treatment protocols including multimodality approaches with neoadjuvant intent. Treatment response might not only serve as a surrogate marker for pathological remission but for overall prognosis as well. Within this context, the optimal time point and the best parameter to evaluate remain issues of continuing debate. This review is aimed to give an overview of the current state of the scientific knowledge.

top of page

Publication History

Cite this article as

Corresponding author e-mail

wouter.vanelmpt@maastro.nl